molecules of the month


oral SAM-competitive PRMT5 inhibitor

Ph. I candidate for solid tumors (adv. or met.)

SBDD utilizing PRMT5:MEP50 w/ A9145C

Molecular Cancer Therapy

Pfizer Oncology

Chemical structure of molecule PF-06939999 Pfizer SAM-competitive PRMT5 inhibitor
1 min read

10.   The Pfizer SAM-competitive PRMT5 inhibitor, PF-06939999 is a Ph. I clinical candidate in dose escalation in solid tumors. Ph. I data has been reported showing signs of early efficacy with cytopenias as common adverse events. This is in agreement with Ph. I data that was recently reported for a JNJ SAM-competitive PRMT5 inhibitor in which thrombocytopenia was identified as a dose-limiting toxicity and an early efficacy signal may have been detected. The Pfizer team suggests that PRMT5i may be especially beneficial in cancers which are dependent on alternative splicing pathways. Furthermore, preclinical resistance studies suggest that complete resistance to SAM site inhibitors may be prevented due to structural constraints in the co-factor binding site. The discovery campaign began with the published crystal structure of PRMT5:MEP50…

request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.

already a member? log in: